Mardia Samyoung Capillary Tubes Company Limited has completed the allotment of 1,30,90,200 fully convertible equity warrants to Torextron Ventures Private Limited on February 05, 2026. The transaction represents the second tranche of the company's preferential allotment program, executed at an issue price of ₹13.50 per warrant.

Warrant Allotment Details

The board of directors approved the allotment during a meeting held on February 05, 2026, at the company's registered office. The warrants carry a premium of ₹3.50 per warrant and were issued in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Regulatory Approvals and Framework

The allotment follows a special resolution passed by members during an Extraordinary General Meeting held on October 29, 2025, which included remote e-voting. The Bombay Stock Exchange granted in-principle approval for the transaction on January 23, 2026. The company has received 25% of the consideration amount from the allottee as mandated under SEBI regulations, with the balance 75% payable upon conversion.

Conversion Terms and Timeline

Each warrant is convertible into an equivalent number of fully paid-up equity shares with a face value of ₹10.00 each. The conversion option must be exercised within 18 months from the allotment date. The number of equity shares to be allotted upon conversion will be subject to appropriate adjustments as permitted under applicable rules and regulations.

Impact on Shareholding Structure

The warrant allotment affects Torextron Ventures Private Limited's position in the company. Prior to the allotment, the entity held 43,88,230 shares representing 23.51% of the pre-issue capital.

*Post-issue shareholding calculated assuming full exercise of warrants and consequent allotment of equity shares.

Corporate Governance Compliance

The board meeting commenced at 3:00 PM and concluded at 3:30 PM on February 05, 2026. The allotment was conducted in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and relevant SEBI circulars. The transaction does not result in any immediate change to the company's paid-up share capital, as the warrants remain unconverted.

Mardia Samyoung Capillary Tubes Company Limited has completed the submission of its unaudited standalone financial results for the third quarter ended December 31, 2025, marking another regulatory milestone for the Mumbai-based company. The submission follows the company's board meeting held on January 24, 2026, where directors formally approved the quarterly financial performance.

Regulatory Compliance and Documentation

The company has fulfilled its obligations under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by submitting newspaper publication copies to BSE Limited. The submission was made on January 28, 2026, with proper documentation including digital signatures from Managing Director Dhaval Dharmendrabhai Joshi.

Company Information and Structure

Mardia Samyoung Capillary Tubes Company Limited operates with its registered office located at A-108, 1st Floor, Chikuwadi, Western Express Highway, Andheri East, Mumbai - 400099. The company maintains its corporate office in Gujarat at Shop-511 Pratik Mall, Near City Pulse Theatre, Kudasan, Gandhi Nagar, Gandhinagar, Gujarat, India, 382421.

The company's CIN L74999MH1992PLC069104 reflects its incorporation in Maharashtra in 1992. Managing Director Dhaval Dharmendrabhai Joshi (DIN: 10778731) oversees the company's operations and regulatory compliance.

Financial Results Accessibility

The detailed quarterly financial results filed under Regulation 33 of the SEBI regulations are accessible through multiple channels. Stakeholders can access the complete financial information on the stock exchange website and the company's official website at https://mardiasamyounglimited.com/ . The company has also provided QR code access for convenient digital viewing of the financial documents.

Board Approval Process

The unaudited standalone financial results received formal approval from the company's board of directors during their meeting on January 24, 2026. This approval process ensures proper governance and oversight of the company's financial reporting, maintaining transparency with shareholders and regulatory authorities.

The submission represents the company's commitment to maintaining regular financial disclosure practices and adhering to stock exchange listing requirements. The availability of results through multiple digital platforms demonstrates the company's focus on stakeholder accessibility and transparency in financial communication.

Source: BSE Filing